Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AB-729 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort A, Group 1 | EXPERIMENTAL | AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to: AB-729 60 mg SC every 8 weeks + NA + Peg-IFNα-2a 180 mcg SC every week for 24 weeks. |
| Cohort A, Group 2 | EXPERIMENTAL | AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to: NA + Peg-IFNα-2a 180 mcg SC every week for 24 weeks. |
| Cohort B, Group 1 | EXPERIMENTAL | AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to: AB-729 60 mg SC every 8 weeks + NA + Peg-IFNα-2a 180 mcg SC every week for 12 weeks. |
| Cohort B, Group 2 | EXPERIMENTAL | AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to: NA + Peg-IFNα-2a 180 mcg SC every week for 12 weeks. |
| Name | Type | Description |
|---|---|---|
| AB-729 | DRUG | subcutaneous injection |
| Peg-IFNα-2a | DRUG | subcutaneous injection |
Inclusion Criteria: * Chronic hepatitis B virus infection with documentation at least 6 months prior to screening * Subjects must have been receiving either TAF, TDF (or equivalent), or ETV consistently for ≥12 months prior to dosing Day 1 * HBV DNA \<LLOQ at Screening * HBsAg between 100 and 5,000...